Sm peptides in differentiation of autoimmune diseases

Advances in Clinical Chemistry

Volumn 54, Issue , 2011, Pages 109-128

  Mahler, Michael ^a  

^a INOVA DIAGNOSTICS INC   (United States)

Author keywords

Autoantibody; Peptide; SLE; Sm

Indexed keywords

AUTOANTIBODY; SMALL NUCLEAR RIBONUCLEOPROTEIN;

AMINO ACID SEQUENCE; BLOOD; BOOK; HUMAN; IMMUNOLOGY; MIXED CONNECTIVE TISSUE DISEASE; MOLECULAR GENETICS; SYSTEMIC LUPUS ERYTHEMATOSUS;

AMINO ACID SEQUENCE; AUTOANTIBODIES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIXED CONNECTIVE TISSUE DISEASE; MOLECULAR SEQUENCE DATA; RIBONUCLEOPROTEINS, SMALL NUCLEAR;

EID: 79953852388     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-387025-4.00005-4     Document Type: Book

References (103)

1. von Muhlen C.A., Tan E.M. Autoantibodies in the diagnosis of systemic rheumatic diseases. Semin. Arthritis Rheum. 1995, 24:323-358.
2. Zieve G.W., Khusial P.R. The anti-Sm immune response in autoimmunity and cell biology. Autoimmun. Rev. 2003, 2:235-240.
3. Tan E.M., Kunkel H.G. Characteristics of a soluble nuclear antigen precipitating with sera of patients with systemic lupus erythematosus. J. Immunol. 1966, 96:464-471.
4. Tsokos G.C. In the beginning was Sm. J. Immunol. 2006, 176:1295-1296.
5. Mattioli M., Reichlin M. Characterization of a soluble nuclear ribonucleoprotein antigen reactive with SLE sera. J. Immunol. 1971, 107:1281-1290.
6. Sherer Y., Gorstein A., Fritzler M.J., Shoenfeld Y. Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin. Arthritis Rheum. 2004, 34:501-537. (Review).
7. Arbuckle M.R., McClain M.T., Rubertone M.V., et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N. Engl. J. Med. 2003, 349:1526-1533.
8. Heinlen L.D., Ritterhouse L.L., McClain M.T., et al. Ribosomal P autoantibodies are present before SLE onset and are directed against non-C-terminal peptides. J. Mol. Med. 2010, 88:719-727.
9. Mahler M., Fritzler M.J. Epitope specificity and significance in systemic autoimmune diseases. Ann. NY Acad. Sci. 2010, 1183:267-287. (Review).
10. Tan E.M., Cohen A.S., Fries J.F., et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982, 25:1271-1277.
11. Sharp G.C., Irvin W.S., LaRoque R.L., et al. Association of autoantibodies to different nuclear antigens with clinical patterns of rheumatic disease and responsiveness to therapy. J. Clin. Invest. 1971, 50:350-359.
12. Sharp G.C., Irvin W.S., Tan E.M., Gould R.G., Holman H.R. Mixed connective tissue disease-an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am. J. Med. 1972, 52:148-159.
13. Maldonado M.E., Perez M., Pignac-Kobinger J., et al. Clinical and immunologic manifestations of mixed connective tissue disease in a Miami population compared to a Midwestern US Caucasian population. J. Rheumatol. 2008, 35:429-437.
14. Vaz C.C., Couto M., Medeiros D., et al. Undifferentiated connective tissue disease: a seven-center cross-sectional study of 184 patients. Clin. Rheumatol. 2009, 28:915-921.
15. Salmhofer W., Hermann J., Joch M., Kerl H., Graninger W. High serum levels of antibodies against the recombinant 70kDa ribonucleoprotein are useful for diagnosing mixed connective tissue disease. J. Eur. Acad. Dermatol. Venereol. 2007, 21(8):1047-1053.
16. Murakami A., Kojima K., Ohya K., Imamura K., Takasaki Y. A new conformational epitope generated by the binding of recombinant 70-kd protein and U1 RNA to anti-U1 RNP autoantibodies in sera from patients with mixed connectivetissue disease. Arthritis Rheum. 2002, 46:3273-3282.
17. Greidinger E.L., Casciola-Rosen L., Morris S.M., Hoffman R.W., Rosen A. Autoantibody recognition of distinctly modified forms of the U1-70-kd antigen is associated with different clinical manifestations. Arthritis Rheum. 2000, 43:881-888.
18. Hof D., Cheung K., de Rooij D.J., et al. Autoantibodies specific for apoptotic U1-70K are superior serological markers for mixed connective tissue disease. Arthritis Res. Ther. 2005, 7:R302-R309.
19. Migliorini P., Baldini C., Rocchi V., Bombardieri S. Anti-Sm and anti-RNP antibodies. Autoimmunity 2005, 38:47-54. (Review).
20. Will C.L., Luhrmann R. Spliceosomal UsnRNP biogenesis, structure and function. Curr. Opin. Cell Biol. 2001, 13:290-301.
21. Hoch S.O. The Sm antigens. Manual of Biological Markers of Disease 1994, 1-29. Kluwer Academic, Dordrecht, The Netherlands, B2.4. R.N. Maini, W.J. van Venrooji (Eds.).
22. Brahms H., Raker V.A., van Venrooij W.J., Lührmann R. A major, novel systemic lupus erythematosus autoantibody class recognizes the E, F, and G Sm snRNP proteins as an E-F-G complex but not in their denatured states. Arthritis Rheum. 1997, 40:672-682.
23. De Keyser F., Hoch S.O., Takei M., et al. Cross-reactivity of the B/B' subunit of the Sm ribonucleoprotein autoantigen with proline-rich polypeptides. Clin. Immunol. Immunopathol. 1992, 62:285-290.
24. Hoch S.O., Eisenberg R.A., Sharp G.C. Diverse antibody recognition patterns of the multiple Sm-D antigen polypeptides. Clin. Immunol. 1999, 92:203-208.
25. McClain M.T., Ramsland P.A., Kaufman K.M., James J.A. Anti Sm autoantibodies in systemic lupus target highly basic surface structures of complexed spliceosomal autoantigens. J. Immunol. 2002, 168:2054-2062.
26. Barakat S., Briand J.P., Weber J.C., Van Regenmortel M.H., Muller S. Recognition of synthetic peptides of Sm-D autoantigen by lupus sera. Clin. Exp. Immunol. 1990, 81:256-262.
27. Sabbatini A., Dolcher M.P., Marchini B., Bombardieri S., Migliorini P. Mapping of epitopes on the SmD molecule: the use of multiple antigen peptides to measure autoantibodies in systemic lupus erythematosus. J. Rheumatol. 1993, 20:1679-1683.
28. James J.A., Mamula M.J., Harley J.B. Sequential autoantigenic determinants of the small nuclear ribonucleoprotein Sm D shared by human lupus autoantibodies and MRL lpr/lpr antibodies. Clin. Exp. Immunol. 1994, 98:419-426.
29. Riemekasten G., Marell J., Trebeljahr G., et al. A novel epitope on the C-terminus of SmD1 is recognized by the majority of sera from patients with systemic lupus erythematosus. J. Clin. Invest. 1998, 102:754-763.
30. James J.A., Gross T., Scofield R.H., Harley J.B. Immunoglobulin epitope spreading and autoimmune disease after peptide immunization: Sm B/B0-derived PPPGMRPP and PPPGIRGP induce spliceosome autoimmunity. J. Exp. Med. 1995, 181:453-461.
31. Arbuckle M.R., Reichlin M., Harley J.B., James J.A. Shared early autoantibody recognition events in the development of anti-Sm B/B' in human lupus. Scand. J. Immunol. 1999, 50:447-455.
32. Fritzler M.J., O'Brien M.D. The purification, characterization and amino acid analysis of nuclear ribonuclear protein and Sm antigens reacting with human autoimmune sera. Clin. Invest. Med. 1983, 6(2):61-71.
33. Brahms H., Meheus L., de Brabandere V., Fischer U., Luhrmann R. Symmetrical dimethylation of arginine residues in spliceosomal Sm protein B/B0 and the Sm-like protein LSm4, and their interaction with the SMN protein. RNA 2001, 7:1531-1542.
34. Brahms H., Raymackers J., Union A., de Keyser F., Meheus L., Lührmann R. The C-terminal RG dipeptide repeats of the spliceosomal Sm proteins D1 and D3 contain symmetrical dimethylarginines, which form a major B-cell epitope for anti-Sm autoantibodies. J. Biol. Chem. 2000, 275:17122-17129.
35. Mahmoudi M., Edwards J.Y., Bell D.A., Cairns E. V region gene analysis of human IgM hybridoma monoclonal anti-Sm antibodies. Lupus 1997, 6:578-589.
36. Tsuzaka K., Ogasawara T., Tojo T., Mimori T., Satoh M., Homma M. Nonprecipitating IgG or IgM anti-Sm antibody: clinical significance and changes in immunoglobulin class. J. Rheumatol. 1993, 20:822-830.
37. Atta A.M., Santiago M.B., Guerra F.G., Pereira M.M. Sousa Atta ML. Autoimmune response of IgE antibodies to cellular self-antigens in systemic Lupus Erythematosus. Int. Arch. Allergy Immunol. 2010, 152:401-406.
38. Golan T.D., Gharavi A.E., Elkon K.B. Penetration of autoantibodies into living epithelial cells. J. Invest. Dermatol. 1993, 100:316-322.
39. Nakamura R.M., Peebles C.L., Tan E.M. Microhemagglutination test for detection of antibodies to nuclear Sm and ribonucleoprotein antigens in systemic lupus erythematosus and related diseases. Am. J. Clin. Pathol. 1978, 70:800-807.
40. Kurata N., Tan E.M. Identification of antibodies to nuclear acid antigens by counterimmunoelectrophoresis. Arthritis Rheum. 1976, 193:574-580.
41. Navarro E., Palau J. Anti-Sm sera are misdetected by counterimmunoelectrophoresis. A critical analysis of CIE and western blotting on the detection of human antinuclear antibodies. J. Autoimmun. 1991, 4:213-222.
42. Westgeest A.A., Van den Brink H.G., de Jong J., Swaak A.J., Smeenk R.J. Routine testing for antinuclear antibodies: a comparison of immunofluorescence, counterimmunoelectrophoresis and immunoblotting. J. Autoimmun. 1988, 1:159-170.
43. Walravens M.J., Vanherrewegwn H., Lacquet F., et al. Counterimmunoelectrophoresis with serum prediffusion: an improved method for the detection and identification of antibodies against extractable nuclear and cytoplasmic antigens. J. Immunol. Methods 1997, 201:89-98.
44. Kallenberg C.G., ter Borg E.J., Jaarsma D., Limburg P.C. Detection of autoantibodies to ribonucleoproteins by counterimmunoelectropheresis, immunoblotting and RNA-immunoprecipitation: comparison of results. Clin. Exp. Rheumatol. 1990, 8:35-40.
45. Westgeest A.A., Van den Brink H.G., de Jong J., et al. Antinuclear antibodies in patients with systemic lupus erythematosus: a comparison of counterimmunoelectrophoresis and immunoblotting. Rheumatol. Int. 1987, 7:77-82.
46. Delpech A., Gilbert D., Daliphard S., Le Loet X., Godin M., Tron F. Antibodies to Sm, RNP and SSB detected by solidphase ELISAs using recombinant antigens: a comparison study with counter immunoelectrophoresis and immunoblotting. J. Clin. Lab. Anal. 1993, 7:197-202.
47. Ou Y., Sun S., Sharp G.C., Hoch S.O. Screening of SLE sera using purified recombinant Sm-D1 protein from a baculovirus expression system. Clin. Immunol. Immunopathol. 1997, 83:310-317.
48. Mahler M., Fritzler M.J., Blüthner M. Identification of a SmD3 epitope with a single symmetrical dimethylation of an arginine residue as specific target of a subpopulation of anti-Sm antibodies. Arthritis Res. Ther. 2005, 7:R19-R29.
49. Phan T.G., Ng W.W., Bird D., et al. High-quality, cost effective strategy for detection of autoantibodies to extractable nuclear antigens. Clin. Diagn. Lab. Immunol. 2001, 8:471-474.
50. Van Duijnhoven H.L.P., Van de Warenburg F.J.M., Willems R.J.W.P., Ermens A.A.M. A comparison of ELISA assays as routine diagnostic test for detection of autoantibodies against extractable nuclear antigens. Clin. Biochem. 1999, 32:179-183.
51. Tan E.M., Smolen J.S., Mc Dougal J.S., et al. Clinical significance of antinuclear antibodies: comparison of detection with immunofluorescence and enzyme-linked immunosorbent assays. Arthritis Rheum. 1997, 40:1612-1618.
52. Tan E.M., Smolen J.S., McDougal J.S., et al. A critical evaluation of enzyme immunoassay kits for detection of antinuclear autoantibodies of defined specificities. II. Potential for quantitation of antibody content. J. Rheumatol. 2002, 29:68-74.
53. Bizzaro N., Tozzoli R., Tonutti E., et al. Variability between methods to determine ANA, anti-dsDNA and anti-ENA autoantibodies: a collaborative study with the biomedical industry. J. Immunol. Methods 1998, 219:99-107.
54. Gonzales C., Martin T., Arroyo T., Garcia-Isidoro M., Navajo J.A., Gonzales-Buitrago J.M. Comparison and variation of different methodologies for the detection of autoantibodies to nuclear antigens (ANA). J. Clin. Lab. Anal. 1997, 11:388-392.
55. Jaskowski T.D., Schroder C., Martins T.B., Mouritsen L., Hill H.R. Comparison of three commercially available enzyme immunoassays for the screening of autoantibodies to extractable nuclear antigens. J. Clin. Lab. Anal. 1995, 9:166-172.
56. Lopez Longo F.J., Rodriguez-Mahou M., Escalona-Monge M., Gonzales C.M., Monteagudo I., Carreno-Perez L. Simultaneous identification of various antinuclear antibodies using an automated multiparameter line immunoassay system. Lupus 2003, 12:623-629.
57. Damoiseaux J., Boesten K., Giesen J., Austen J., Tervaert J.W. Evaluation of a novel line-blot immunoassay for the detection of antibodies to extractable nuclear antigens. Ann. NY Acad. Sci. 2005, 1050:340-347.
58. Eissfeller P., Sticherling M., Scholz D., et al. Comparison of different test systems for simultaneous autoantibody detection in connective tissue diseases. Ann. NY Acad. Sci. 2005, 1050:327-339.
59. Hoffman I.E., Peene I., Meheus L., Huizinga T.W., Cebecauer L., Isenberg D.., et al. Specific antinuclear antibodies are associated with clinical features in systemic lupus erythematosus. Ann. Rheum. Dis. 2004, 63:1155-1158.
60. Robinson W.H., DiGennaro C., Hueber W., et al. Autoantigen microarrays for multiplex characterization of autoantibody responses. Nat. Med. 2002, 8:295-301.
61. Hueber W., Utz P.J., Steinman L., Robinson W.H. Autoantibody profiling for the study and treatment of autoimmune disease. Arthritis Res. 2002, 4:290-295. (Review).
62. Pang S., Smith J., Onley D., Reeve J., Walker M., Foy C. A comparability study of the emerging protein array platforms with established ELISA procedures. J. Immunol. Methods 2005, 302(1-2):1-12.
63. Hanly J.G., Su L., Farewell V., Fritzler M.J. Comparison between multiplex assays for autoantibody detection in systemic lupus erythematosus. J. Immunol. Methods 2010, 30(358):75-80.
64. Zandman-Goddard G., Gilburd B., et al. The homogeneous multiplexed system-a new method for autoantibody profile in systemic lupus erythematosus. Clin. Dev. Immunol. 2005, 12:107-111.
65. Copple S.S., Martins T.B., Masterson C., Joly E., Hill H.R. Comparison of three multiplex immunoassays for detection of antibodies to extractable nuclear antibodies using clinically defined sera. Ann. NY Acad. Sci. 2007, 1109:464-472.
66. Hanly J.G., Thompson K., McCurdy G., Fougere L., Theriault C., Wilton K. Measurement of autoantibodies using multiplex methodology in patients with systemic lupus erythematosus. J. Immunol. Methods 2010, 352:147-152.
67. McBride J.D., Gabriel F.G., Fordham J., et al. Screening autoantibody profiles in systemic rheumatic disease with a diagnostic protein microarray that uses a filtration-assisted nanodot array luminometric immunoassay (NALIA). Clin. Chem. 2008, 54:883-890.
68. Smith J., Onley D., Garey C., Crowther S., Cahir N., Johanson A., et al. Determination of ANA specificity using the UltraPlex platform. Ann. NY Acad. Sci. 2005, 1050:286-294.
69. Mahler M., Stinton L.M., Fritzler M.J. Improved serological differentiation between systemic lupus erythematosus and mixed connective tissue disease by use of an SmD3 peptide-based immunoassay. Clin. Diagn. Lab. Immunol. 2005, 12:107-113.
70. Jaekel H.P., Klopsch T., Benkenstein B., et al. Reactivities to the Sm autoantigenic complex and the synthetic SmD1-aa83-119 peptide in systemic lupus erythematosus and other autoimmune diseases. Autoimmunity 2001, 17:347-354.
71. Dieker J.W., Van Bavel C.C., Riemekasten G., Berden J.H., van der Vlag J. The binding of lupus-derived autoantibodies to the C-terminal peptide (83-119) of the major SmD1 autoantigen can be mediated by double-stranded DNA and nucleosomes. Ann. Rheum. Dis. 2006, 65:1525-1528.
72. Mahler M., Waka A., Hiepe F., Fritzler M.J. Effect of dsDNA binding to SmD-derived peptides on clinical accuracy in the diagnosis of systemic lupus erythematosus. Arthritis Res. Ther. 2007, 9:R68.
73. del Rincon I., Zeidel M., Rey E., Harley J.B., James J.A., Fischbach M., Sanz I. Delineation of the human systemic lupus erythematosus anti-Smith antibody response using phage-display combinatorial libraries. J. Immunol. 2000, 165:7011-7016.
74. Janwityanuchit S., Verasertniyom O., Vanichapuntu M., Vatanasuk M. Anti-Sm: its predictive value in systemic lupus erythematosus. Clin. Rheumatol. 1993, 12:350-353.
75. ter Borg E.J., Groen H., Horst G., Limburg P.C., Wouda A.A., Kallenberg C.G. Clinical associations of antiribonucleoprotein antibodies in patients with systemic lupus erythematosus. Semin. Arthritis Rheum. 1990, 20:164-173.
76. Grennan D.M., Bunn C., Hughes G.R., Buchanan W.W., Dick W.C. Frequency and clinical significance of antibodies to ribonucleoprotein in SLE and other connective tissue disease subgroups. Ann. Rheum. Dis. 1977, 36:442-447.
77. Winfield J.B., Brunner C.M., Koffler D. Serologic studies in patients with systemic lupus erythematosus and central nervous system dysfunction. Arthritis Rheum. 1978, 21:289-294.
78. Winn D.M., Wolfe J.F., Lindberg D.A., Fristoe F.H., Kingsland L., Sharp G.C. Identification of a clinical subset of systemic lupus erythematosus by antibodies to the SM antigen. Arthritis Rheum. 1979, 22:1334-1337.
79. Alba P., Bento L., Cuadrado M.J., et al. Anti-dsDNA, anti-Sm antibodies, and the lupus anticoagulant: significant factors associated with lupus nephritis. Ann. Rheum. Dis. 2003, 62:556-560.
80. Bastian H.M., Roseman J.M., McGwin G., et al. LUMINA Study Group. LUpus in MInority populations: NAture vs nurture. Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. Lupus 2002, 11:152-160.
81. Barada F.A., Andrews B.S., Davis J.S., Taylor R.P. Antibodies to Sm in patients with systemic lupus erythematosus. Correlation of Sm antibody titers with disease activity and other laboratory parameters. Arthritis Rheum. 1981, 24:1236-1244.
82. Gripenberg M., Teppo A.M., Friman C. Antibodies to Sm and SS-A demonstrated by enzyme immunoassay. Correlation to clinical manifestations and disease activity in patients with systemic lupus erythematosus. Rheumatol. Int. 1991, 11:209-213.
83. Agarwal S., Harper J., Kiely P.D. Concentration of antibodies to extractable nuclear antigens and disease activity in systemic lupus erythematosus. Lupus 2009, 18:407-412.
84. Prasad R., Ibañez D., Gladman D., Urowitz M. Anti-dsDNA and anti-Sm antibodies do not predict damage in systemic lupus erythematosus. Lupus 2006, 15:285-291.
85. Paz M.L., González Maglio D.H., Pino M., et al. Anti-ribonucleoproteins autoantibodies in patients with systemic autoimmune diseases. Relation with cutaneous photosensitivity. Clin. Rheumatol. 2011, 30:209-216.
86. AlSaleh J., Jassim V., ElSayed M., Saleh N., Harb D. Clinical and immunological manifestations in 151 SLE patients living in Dubai. Lupus 2008, 17:62-66.
87. Jallouli M., Frigui M., Hmida M.B., Marzouk S., Kaddour N., Bahloul Z. Clinical and immunological manifestations of systemic lupus erythematosus: study on 146 south Tunisian patients. Saudi J. Kidney Dis. Transpl. 2008, 19:1001-1008.
88. Al-Jabri A.A., Al-Gahdani A.K., Al-Shuaili I. High frequency of Smith autoantibodies in Omani patients with systemic lupus erythematosus. Rheumatol. Int. 2009, 30:51-56.
89. Al Arfaj A.S., Khalil N. Clinical and immunological manifestations in 624 SLE patients in Saudi Arabia. Lupus 2009, 18:465-473.
90. Ni J.D., Yao X., Pan H.F., Li X.P., Xu J.H., Ye D.Q. Clinical and serological correlates of anti-Sm autoantibodies in Chinese patients with systemic lupus erythematosus: 1,584 cases. Rheumatol. Int. 2009, 29:1323-1326.
91. Tang X., Huang Y., Deng W., Tang L., Weng W., Zhang X. Clinical and serologic correlations and autoantibody clusters in systemic lupus erythematosus: a retrospective review of 917 patients in South China. Medicine (Baltimore) 2010, 89:62-67.
92. Li L.H., Pan H.F., Li W.X., Li X.P., Xu J.H., Ye D.Q. Study on clinical features and complications with systemic lupus erythematosus (SLE) activity in Chinese Han population. Clin. Rheumatol. 2009, 28:1301-1307.
93. Shovman O., Gilburd B., Zandman-Goddard G., Yehiely A., Langevitz P., Shoenfeld Y. Multiplexed AtheNA multi-lyte immunoassay for ANA screening in autoimmune diseases. Autoimmunity 2005, 38:105-109.
94. Arnett F.C., Hamilton R.G., Roebber M.G., Harley J.B., Reichlin M. Increased frequencies of Sm and nRNP autoantibodies in American blacks compared to whites with systemic lupus erythematosus. J. Rheumatol. 1988, 15:1773-1776.
95. Thorley-Lawson D.A. Epstein-Barr virus: exploiting the immune system. Nat. Rev. Immunol. 2001, 1:75-82.
96. Sabbatini A., Bombardieri S., Migliorini P. Autoantibodies from patients with systemic lupus erythematosus bind a shared sequence of SmD and Epstein-Barr virus-encoded nuclear antigen EBNA I. Eur. J. Immunol. 1993, 23:1146-1152.
97. Poole B.D., Gross T., Maier S., Harley J.B., James J.A. Lupus-like autoantibody development in rabbits and mice after immunization with EBNA-1 fragments. J. Autoimmun. 2008, 31:362-371.
98. James J.A., Kaufman K.M., Farris A.D., Taylor-Albert E., Lehman T.J., Harley J.B. An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. J. Clin. Invest. 1997, 100:3019-3026.
99. James J.A., Neas B.R., Moser K.L., et al. Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure. Arthritis Rheum. 2001, 44:1122-1126.
100. Marchini B., Dolcher M.P., Sabbatini A., Klein G., Migliorini P. Immune response to different sequences of the EBNA I molecule in Epstein-Barr virus-related disorders and in autoimmune diseases. J. Autoimmun. 1994, 7:179-191.
101. Mahler M., Mierau R., Schlumberger W., Blüthner M. A population of autoantibodies against a centromere-associated protein A major epitope motif cross-reacts with related cryptic epitopes on other nuclear autoantigens and on the Epstein-Barr nuclear antigen 1. J. Mol. Med. 2001, 79:722-731.
102. Eystathioy T., Peebles C., Hamel J.C., Vaughan J.H., Chan E.K.L. Autoantibody to hLSm4 and the hepatameric LSm complex in anti-Sm sera. Arthritis Rheum. 2002, 46:726-734.
103. Poole B.D., Scofield R.H., Harley J.B., James J.A. Epstein-Barr virus and molecular mimicry in systemic lupus erythematosus. Autoimmunity 2006, 39(1):63-70.